Why the study?
Does an IL-8 targeted ultrasound contrast agent improve the detection of atherosclerotic plaques in a rabbit model compared to non-targeted contrast agent?
Does an IL-8 targeted ultrasound contrast agent improve the detection of atherosclerotic plaques in a rabbit model compared to non-targeted contrast agent?
An IL-8-targeted ultrasound contrast agent improves the detection sensitivity of atherosclerotic plaques in a rabbit model compared to non-targeted microbubbles.
Answers are grounded in this paper and cite their sources.
May improve plaque detection in rabbit models; hypothesis-generating for targeted ultrasound contrast agents pending human validation.
In this study, we aimed to prepare a neovascularization-relevant inflammatory cytokine-targeted ultrasound contrast agent and apply it in the ultrasound imaging of atherosclerotic plaque. An interleukin-8 (IL-8) monoclonal antibody was conjugated to SonoVue microbubbles using the N-succinimidyl-3-(2-pyridyldithio)propionate cross-linking method. Then, a prepared IL-8-targeted contrast agent was used for contrast-enhanced ultrasound (CEU) to detect rabbit abdominal aorta atherosclerotic plaque and to investigate the imaging characteristics of atherosclerotic plaque with the contrast agent. We found that an IL-8 monoclonal antibody can be successfully coupled to SonoVue microbubbles with stable biological characteristics. CEU with this IL-8-targeted contrast agent can increase the atherosclerotic plaque detection sensitivity, with stronger echo, so that three more plaques were detected compared with using non-targeted SonoVue microbubbles. Thus, an inflammatory cytokine-targeting ultrasound contrast agent carrying IL-8 monoclonal antibody can provide unique advantages for researching the characteristics of atherosclerotic plaque.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: